Litigation Details for Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2024)
✉ Email this page to a colleague
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2024)
| Docket | ⤷ Sign Up | Date Filed | 2024-06-20 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 7,608,261; 8,092,803 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2024-07-17 | 21 | the ’594 patent, the Examiner rejected the claims for OTDP over U.S. Patent No. 7,608,261 (“the ’261… 7,608,261 8 2 t l 0/2009 Furfine (22) Filed: Jan…Attorney, Agent, or Finn - Karl Bozicevic; 7,608,261. … -5% of one or more organic co- U.S. Pat. No. 7,608,261 on Oct. 27, 2009, which claims the solvent…if the ’594 patent were a proper reference patent, the ’865 patent is allegedly patentably distinct from | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
